Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sirolimus
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Whitehawk Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement
Details : The combined, publicly traded company will focus on the advancement, expansion and commercialization of Aadi’s clinical stage pipeline, including Aadi’s lead program for its nanoparticle albumin-bound mTOR inhibitor, FYARRO™, an mTOR inhibitor boun...
Product Name : Fyarro
Product Type : Antibiotic
Upfront Cash : Undisclosed
August 26, 2021
Lead Product(s) : Sirolimus
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Whitehawk Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Sirolimus
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Whitehawk Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement
Details : Following the proposed merger, Aerpio will change its name to “Aadi Bioscience, Inc.” and the combined public company will focus on advancing Aadi’s lead product candidate, FYARROTM (sirolimus albumin-bound nanoparticles for injectable suspension; ...
Product Name : Fyarro
Product Type : Antibiotic
Upfront Cash : Undisclosed
May 17, 2021
Lead Product(s) : Sirolimus
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Whitehawk Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Razuprotafib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Quantum Leap Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The I-SPY COVID Trial was halted by Quantum Leap Healthcare Collaborative because Aerpio's razuprotafib was difficult to administer in the setting of COVID-19, with 30% of patients discontinuing the agent due to disease-related hypotension.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 03, 2021
Lead Product(s) : Razuprotafib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Quantum Leap Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GB004
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Gossamer Bio
Deal Size : $105.0 million
Deal Type : Licensing Agreement
Details : The renegotiated licensing deal is intended to place Gossamer Bio in a better position to progress GB004, and in addition, is designed to facilitate the further development of each company’s respective pipelines.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $15.0 million
December 05, 2020
Lead Product(s) : GB004
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Gossamer Bio
Deal Size : $105.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Razuprotafib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Razuprotafib a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase, is being developed as a treatment for open angle glaucoma, and the Company intends to investigate the therapeutic potential of razuprotafib in ot...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2020
Lead Product(s) : Razuprotafib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Razuprotafib,Prostaglandin
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort
Details : The Phase 1b trial is a randomized, double-masked study designed to assess increasing concentrations of AKB-9778 dosed topically as eye drops.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2020
Lead Product(s) : Razuprotafib,Prostaglandin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Razuprotafib
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma Trial
Details : The study is designed to evaluate the safety and efficacy of a topical ocular formulation of razuprotafib in approximately 195 patients followed over a 28-day period, and patients must undergo a 28-day washout prior to randomization.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2020
Lead Product(s) : Razuprotafib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Razuprotafib,Prostaglandin
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Topical ocular administration of AKB-9778 was well tolerated over seven days in cohort 5.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2020
Lead Product(s) : Razuprotafib,Prostaglandin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Razuprotafib
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial
Details : Aerpio Pharmaceuticals has commenced patient enrollment in its double-blind, placebo-controlled Phase 2 trial in patients with elevated intraocular pressure (IOP) associated with open angle glaucoma (OAG) or ocular hypertension (OHT).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 24, 2020
Lead Product(s) : Razuprotafib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Razuprotafib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Quantum Leap Healthcare
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims at evaluating razuprotafib in a new randomized, investigational treatment arm in the I-SPY COVID Trial for the treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 27, 2020
Lead Product(s) : Razuprotafib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Quantum Leap Healthcare
Deal Size : Undisclosed
Deal Type : Collaboration